We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Medicinal Products

Summary

The Deputy questioned whether limited negotiations over Pluvicto met timely-access and pricing-framework commitments; the Minister referred the matter to the HSE.

2179. Deputy Michael Fitzmaurice asked the Minister for Health her views on whether two commercial negotiation meetings between the HSE and the applicant (details supplied), in the 45 months since the reimbursement application for pluvicto was received in January 2023 is consistent with the commitment to equitable and timely access to new medicines in the National Cancer Strategy; and if it is in line with the targets set by the Framework Agreement on the Supply and Pricing of Medicines. [77167/26]

Comment on this

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Comment on this